Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Account Payables (2020 - 2025)

Tango Therapeutics has reported Change in Account Payables over the past 6 years, most recently at -$1.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$1.2 million for Q4 2025, up 50.9% from a year ago — trailing twelve months through Dec 2025 was -$825000.0 (up 30.32% YoY), and the annual figure for FY2025 was -$825000.0, up 30.32%.
  • Change in Account Payables for Q4 2025 was -$1.2 million at Tango Therapeutics, down from -$344000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for TNGX hit a ceiling of $4.5 million in Q3 2022 and a floor of -$2.8 million in Q2 2024.
  • Median Change in Account Payables over the past 5 years was -$351500.0 (2022), compared with a mean of -$69250.0.
  • Peak annual rise in Change in Account Payables hit 43536.36% in 2021, while the deepest fall reached 36537.56% in 2021.
  • Tango Therapeutics' Change in Account Payables stood at $365000.0 in 2021, then crashed by 384.93% to -$1.0 million in 2022, then soared by 91.54% to -$88000.0 in 2023, then plummeted by 2748.86% to -$2.5 million in 2024, then skyrocketed by 50.9% to -$1.2 million in 2025.
  • The last three reported values for Change in Account Payables were -$1.2 million (Q4 2025), -$344000.0 (Q3 2025), and -$880000.0 (Q2 2025) per Business Quant data.